Although remarkable progress has been made in defining and treating mental illnesses, some treatments are not effective for all persons or may have significant side effects.

In providing support for global psychiatric drug development programs, we bring customers a team with vast mental-health clinical research experience. We have access to leading academic and private practice investigative sites, whose specialty is evaluating, diagnosing and treating the psychiatric patient populations customers seek.

We've worked across all psychiatric indications including addiction, ADD/ADHD, Anxiety, Bipolar Disorder, Depression, Panic, Schizophrenia, and Smoking Cessation. We know many factors greatly influence the outcome of psychiatric clinical trials. Rater reliability, placebo response rates, study design and methodology, patient expectations and the quality of patient-physician interaction are all factors to consider. Andronovo CNS addresses these important issues and provides expertise to facilitate discovery of safe and effective treatments for mental disorders.

For more information on Andronovo’s therapeutic expertise in Psychiatry, click here.